Etoricoxib

Second quarter 2023 revenue of $1,608 million Second quarter 2023 diluted earnings per share of $0.95 and non-GAAP Adjusted diluted earnings per share of $1.31 Adjusted EBITDA of $530 million Board of Directors declares quarterly dividend of $0.28 per share Full year 2023 financial guidance ranges updated: Revenue range narrowed to $6.25 billion to $6.45 billion, primarily reflecting current foreign currency exchange rates Adjusted EBITDA margin range now 31.5%-33.0% to incorporate current visibility on IPR&D (in-process research and development) and milestones JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN) today announced its results for the second quarter ended June 30, 2023. "During the second quarter of 2023, Organon continued to build on its track record, delivering solid volume growth across all regions and franchises. The Women's Health and Biosimilars franchise revenue grew 10% and 15% excluding the impact of foreign currency ("ex-FX"), respectively, and Established Brands continued to demonstrate stability," said Kevin Ali, Organon's CEO. "Further, on July 1st we launched Hadlima™ (adalimumab-bwwd) in the United States - so far our biggest commercial launch in the U.S. as a standalone company. Hadlima is emerging as one of a few biosimilars offerings earning commercial success so far. We are encouraged by our early traction and remain confident in our strategy, the attributes of our product and our collaborator's capabilities to deliver reliable supply." Second Quarter 2023 Revenue in $ millions Q2 2023 Q2 2022 VPY VPY ex-FX Women’s Health $ 438 $ 408 8% 10% Biosimilars 135 119 14% 15% Established Brands 995 1,018 (2)% —% Other (1) 40 40 (2)% (1)% Revenues $ 1,608 $ 1,585 1% 4% (1) Other includes manufacturing sales to Merck & Co., Inc., Rahway, NJ, USA and other third parties. For the second quarter of 2023, total revenue was $1,608 million, an increase of 1% as-reported and an increase of 4% excluding the impact of foreign currency (ex-FX), compared with the second quarter of 2022. Women’s Health revenue increased 8% on an as-reported basis, and increased 10% ex-FX in the second quarter of 2023 compared with the second quarter of 2022 driven primarily by a 12% ex-FX increase in Nexplanon® (etonogestrel implant), a long-acting reversible contraceptive. The Women's Health franchise also benefited from 17% ex-FX growth in the fertility portfolio during the quarter due to COVID-19 recovery in China as well as strong demand in the LAMERA region and in the U.S. Growth in the Women's Health franchise was partially offset by a 3% ex-FX decrease of NuvaRing® (etonogestrel/ethinyl estradiol vaginal ring) which continues to be impacted by generic competition. Biosimilars revenue increased 14% as-reported and 15% ex-FX in the second quarter of 2023, compared with the second quarter of 2022 primarily driven by Renflexis® (infliximab-abda) which grew 20% ex-FX due to continued demand and strong volume growth in United States and Canada. Growth in the biosimilars franchise was partially offset by a 7% ex-FX decline in Ontruzant® (trastuzumab-dttb) primarily related to ongoing competitive pressures in Europe. On July 1, 2023, the company launched Hadlima, a biosimilar to Humira (adalimumab) (a trademark of AbbVie Biotechnology Ltd.) in the United States. Organon already markets Hadlima in Canada and Australia. Established Brands revenue decreased 2% as-reported and was flat ex-FX in the second quarter of 2023, despite the negative impact from Volume Based Procurement (VBP) initiatives in China and the year over year impact of the company's market action taken in the first quarter of 2023 on select injectable steroids, Diprospan™ (bethamethasone), and Celestone Chronodose™ (bethamethasone), and Celestone Soluspan™ (bethamethasone). Offsetting factors included an 18% ex-FX year over year increase in Atozet™ (ezetimibe and atorvastatin calcium) which was driven by increased demand in the EUCAN region, as well as 23% ex-FX growth in Arcoxia™ (etoricoxib) which was driven by increased volume in the LAMERA region. Year to date, the Established Brands portfolio has grown 1% ex-FX, as 2% volume growth has offset an approximate 1% decline in price across the portfolio. The company continues to expect the Established Brands franchise to achieve flat revenue growth for the full year 2023. Second Quarter 2023 Profitability in $ millions, except per share amounts Q2 2023 Q2 2022 VPY Revenues $ 1,608 $ 1,585 1% Cost of sales 640 588 9% Gross profit 968 997 (3)% Non-GAAP Adjusted gross profit (1) 1,012 1,047 (3)% Adjusted EBITDA (1,2) 530 512 4% Net income 242 234 3% Non-GAAP Adjusted net income (1) 336 319 5% Diluted Earnings per Share (EPS) 0.95 0.92 3% Non-GAAP Adjusted diluted EPS (1) 1.31 1.25 5% Acquired in-process research & development (IPR&D) and milestones — 97 NM Per share impact to diluted EPS from acquired IPR&D and milestones — (0.30) NM Q2 2023 Q2 2022 Gross margin 60.2% 62.9% Non-GAAP Adjusted gross margin (1) 62.9% 66.1% Adjusted EBITDA margin (1,2) 33.0% 32.3% (1) See Tables 4 and 5 for reconciliations of GAAP to non-GAAP financial measures (2) Adjusted EBITDA and Adjusted EBITDA margin include $97 million in the second quarter of 2022 related to acquired IPR&D and milestones, no such expense was incurred in the second quarter of 2023 Gross margin was 60.2% as-reported and 62.9% on an adjusted basis in the second quarter of 2023 compared to 62.9% as-reported and 66.1% on an adjusted basis in the second quarter of 2022. The year-over-year decline in gross margin is primarily due to product mix as well as employee-related costs and distribution related costs, which increased as a result of inflationary pressures in 2023. Adjusted EBITDA margin was 33.0% in the second quarter of 2023 compared to 32.3% in the second quarter of 2022. The increase in Adjusted EBITDA margin was primarily a result of $97 million of IPR&D and milestones in the second quarter of 2022; no such costs were incurred in the second quarter of 2023. Net income for the second quarter of 2023 was $242 million, or $0.95 per diluted share, compared with $234 million, or $0.92 per diluted share, in the second quarter of 2022. Non-GAAP Adjusted net income was $336 million, or $1.31 per diluted share, compared with $319 million, or $1.25 per diluted share, in 2022. The year over year increase in net income was a result of higher Adjusted EBITDA compared with the second quarter of 2022 as well as a tax benefit in the second quarter of 2023 related to earnings outside of the U.S., partially offset by higher interest expense associated with the company's variable rate debt. Capital Allocation Today, Organon’s Board of Directors declared a quarterly dividend of $0.28 for each issued and outstanding share of the company's common stock. The dividend is payable on September 14, 2023, to stockholders of record at the close of business on August 18, 2023. As of June 30, 2023, cash and cash equivalents were $326 million, and debt was $8.7 billion. Full Year Guidance Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon’s results computed in accordance with GAAP. The company is updating its full year 2023 guidance ranges previously provided on May 4, 2023. The range for full year 2023 revenue is narrowed to $6.25 billion to $6.45 billion, which primarily reflects current foreign currency exchange rates. The range for full year Adjusted EBITDA margin is now 31.5% to 33.0% to incorporate the company's current visibility of IPR&D and milestone expenses expected to be incurred in 2023. Organon's financial guidance does not assume an estimate for future IPR&D and milestone payments for business development transactions not yet executed. Full year 2023 financial guidance is presented below on a non-GAAP basis. Previous guidance as of May 4, 2023 Current guidance Revenues $6.150B - $6.450B $6.250B-$6.450B Adjusted gross margin Low-mid 60% range Unchanged SG&A (as % of revenue) Mid 20% range Unchanged R&D (as % of revenue) Upper single-digit Unchanged Adjusted EBITDA margin 31.0%-33.0% 31.5%-33.0% Interest ~$515 million ~$525 million Depreciation ~$130 million ~$120 million Effective non-GAAP tax rate 19.0% - 21.0% 17.5% - 19.5% Fully diluted weighted average shares outstanding ~257 million Unchanged Webcast Information Organon will host a conference call at 8:30 a.m. Eastern Time today to discuss its second quarter 2023 financial results. To listen to the event and view the presentation slides via webcast, join from the Organon Investor Relations website at . A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website. Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call. About Organon Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets. Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey. For more information, visit and connect with us on LinkedIn, Instagram, Twitter and Facebook. Cautionary Note Regarding Non-GAAP Financial Measures This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are correspondingly not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Specifically, the company makes use of the non-GAAP financial measures Adjusted EBITDA, Adjusted gross margin, Adjusted gross profit, Adjusted net income, and Adjusted diluted EPS, which are not recognized terms under GAAP and are presented only as a supplement to the company’s GAAP financial statements. This press release also provides certain measures that exclude the impact of foreign exchange. We calculate foreign exchange by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. The company believes that these non-GAAP financial measures help to enhance an understanding of the company’s financial performance. However, the presentation of these measures has limitations as an analytical tool and should not be considered in isolation, or as a substitute for the company’s results as reported under GAAP. Because not all companies use identical calculations, the presentations of these non-GAAP measures may not be comparable to other similarly titled measures of other companies. You should refer to Table 4 and Table 5 of this press release for relevant definitions and reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. In addition, the company’s full-year 2023 guidance measures (other than revenue) are provided on a non-GAAP basis because the company is unable to reasonably predict certain items contained in the GAAP measures. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts and other items not reflective of the company's ongoing operations. The company uses non-GAAP financial measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful representation of the underlying operating performance of the business. Cautionary Note Regarding Forward-Looking Statements Except for historical information, this press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, an inability to fully execute on our product development and commercialization plans within the United States or internationally; changes in tax laws or other tax guidance which could adversely affect our cash tax liability, effective tax rates, and results of operations and lead to greater audit scrutiny; an inability to execute on our business development strategy or realize the benefits of our planned acquisitions; efficacy, safety, or other quality concerns with respect to marketed products, including market actions such as recalls, withdrawals, or declining sales; political and social pressures, or regulatory developments, that adversely impact demand for, availability of, or patient access to contraception or fertility products; general economic factors, including recessionary pressures, interest rate and currency exchange rate fluctuations; general industry conditions and competition; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; difficulties developing and sustaining relationships with commercial counterparties; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission ("SEC"), including the company’s Annual Report on Form 10-K for the year ended December 31, 2022, available at the SEC’s Internet site ( ). TABLE 1 Organon & Co. Condensed Consolidated Statement of Income (Unaudited, $ in millions except shares in thousands and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Revenues $ 1,608 $ 1,585 $ 3,146 $ 3,152 Costs, Expenses and Other Cost of sales 640 588 1,220 1,149 Selling, general and administrative 451 423 886 794 Research and development 128 106 257 202 Acquired in-process research and development and milestones — 97 8 97 Restructuring costs — — 4 — Interest expense 132 98 264 195 Exchange losses (gains) 2 (21 ) 11 (25 ) Other expense, net 1 7 7 11 1,354 1,298 2,657 2,423 Income Before Income Taxes 254 287 489 729 Taxes on income 12 53 70 147 Net Income 242 234 419 582 Earnings per Share: Basic $ 0.95 $ 0.92 $ 1.64 $ 2.29 Diluted $ 0.95 $ 0.92 $ 1.64 $ 2.28 Weighted Average Shares Outstanding: Basic 255,341 254,018 254,869 253,802 Diluted 255,953 255,156 256,064 255,105 TABLE 2 Organon & Co. Sales by top products (Unaudited, $ in millions) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total U.S. Int’l Total Women’s Health Nexplanon/Implanon NXT $ 159 $ 56 $ 214 $ 134 $ 61 $ 195 $ 272 $ 107 $ 380 $ 250 $ 116 $ 366 Follistim AQ 26 44 70 23 35 58 52 73 125 52 66 119 NuvaRing 17 23 40 22 20 42 33 47 80 38 45 83 Ganirelix Acetate Injection 4 29 34 6 25 32 11 53 63 14 47 61 Marvelon/Mercilon — 29 29 — 31 31 — 67 67 — 54 54 Other Women's Health (1) 27 25 52 29 22 51 53 52 105 56 47 103 Biosimilars Renflexis 60 11 70 51 8 59 114 18 132 93 12 105 Ontruzant 12 21 33 12 23 35 25 29 54 19 38 57 Brenzys — 13 13 — 14 14 — 32 32 — 28 28 Aybintio — 12 12 — 9 9 — 22 22 — 19 19 Hadlima — 7 7 — 2 2 — 12 12 — 8 8 Established Brands Cardiovascular Zetia 2 89 90 2 99 101 4 169 173 5 195 200 Vytorin 1 37 38 3 32 35 3 65 67 5 68 73 Atozet — 143 143 — 122 122 — 271 271 — 240 240 Rosuzet — 17 17 — 16 16 — 35 35 — 38 38 Cozaar/Hyzaar 2 69 71 2 91 92 4 152 156 10 176 186 Other Cardiovascular (1) 1 41 41 1 45 46 1 81 82 2 83 85 Respiratory Singulair 3 77 80 3 89 92 5 194 199 5 216 222 Nasonex — 64 64 — 58 58 — 133 133 9 123 133 Dulera 38 10 48 36 12 47 76 18 95 67 21 88 Clarinex 1 38 39 1 34 35 2 77 79 2 70 73 Other Respiratory (1) 13 6 19 11 11 22 25 12 37 23 22 45 Non-Opioid Pain, Bone and Dermatology Arcoxia — 72 72 — 61 61 — 143 143 — 121 121 Fosamax 1 44 44 1 39 40 1 81 82 2 79 81 Diprospan — 12 12 — 31 31 — 27 27 — 63 63 Other Non-Opioid Pain, Bone and Dermatology (1) 2 67 71 5 71 76 7 127 133 8 137 145 Other Proscar — 24 25 — 26 26 1 51 52 1 50 50 Propecia 2 35 36 2 33 35 4 66 69 3 63 66 Other (1) 2 81 84 7 74 82 4 156 162 15 149 164 Other (2) (2 ) 41 40 — 40 40 — 79 79 1 78 76 Revenues $ 371 $ 1,237 $ 1,608 $ 351 $ 1,234 $ 1,585 $ 697 $ 2,449 $ 3,146 $ 680 $ 2,472 $ 3,152 Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies. (1) Includes sales of products not listed separately. Revenues from Marvelon™ and Mercilon™ were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health. (2) Other includes manufacturing sales to Merck & Co., Inc., Rahway, NJ, USA and other third parties. TABLE 3 Organon & Co. Sales by geographic area (Unaudited, $ in millions) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Europe and Canada $ 467 $ 443 $ 867 $ 880 United States 371 351 697 680 Asia Pacific and Japan 261 291 585 604 China 234 244 459 480 Latin America, Middle East, Russia and Africa 234 216 448 425 Other (1) 41 40 90 83 Revenues $ 1,608 $ 1,585 $ 3,146 $ 3,152 (1) Other includes manufacturing sales to Merck & Co., Inc., Rahway, NJ, USA and other third parties. TABLE 4 Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited, $ in millions except per share amounts) Three Months Ended June 30, 2023 GAAP Spin related Costs(1) Restructuring Stock-based Compensation Amortization Other(1) Non-GAAP Adjusted Revenues $ 1,608 $ 1,608 Cost of sales 640 (10 ) — (4 ) (30 ) — 596 Gross profit 968 1,012 Gross margin 60.2 % 62.9 % Selling, general and administrative 451 (44 ) — (17 ) — — 390 Research and development 128 (3 ) — (4 ) — — 121 Acquired in-process research and development and milestones — — — — — — — Restructuring costs — — — — — — — Interest expense 132 — — — — — 132 Exchange losses 2 — — — — — 2 Other expense (income), net 1 (4 ) — — — — (3 ) 1,354 1,238 Income before income taxes 254 370 Taxes on income 12 13 — 4 5 — 34 Net income $ 242 $ 336 Earnings per share - Diluted $ 0.95 $ 1.31 (1) Represents one-time costs. Spin-related includes costs from the separation of Merck & Co., Inc., Rahway, NJ, US and Other primarily includes inventory step-up amortization and legal reserves. Three Months Ended June 30, 2022 GAAP Spin related Costs(1) Restructuring Stock-based Compensation Amortization Other(1) Non-GAAP Adjusted Revenues $ 1,585 $ 1,585 Cost of sales 588 (6 ) — (3 ) (28 ) (13 ) 538 Gross profit 997 1,047 Gross margin 62.9 % 66.1 % Selling, general and administrative 423 (28 ) — (13 ) — — 382 Research and development 106 (3 ) — (3 ) — — 100 Acquired in-process research and development and 97 — — — — — 97 Restructuring costs — — — — — — — Interest expense 98 — — — — — 98 Exchange gains (21 ) — — — — — (21 ) Other expense (income), net 7 (8 ) — — — — (1 ) 1,298 1,193 Income before income taxes 287 392 Taxes on income 53 10 — 3 4 3 73 Net income $ 234 $ 319 Earnings per share - Diluted $ 0.92 $ 1.25 (1) Represents one-time costs. Spin-related includes costs from the separation of Merck & Co., Inc., Rahway, NJ, US and Other primarily includes inventory step-up amortization and legal reserves. TABLE 4 (Continued) Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited, $ in millions except per share amounts) Six Months Ended June 30, 2023 GAAP Spin related Costs(1) Restructuring Stock-based Compensation Amortization Other(1) Non-GAAP Adjusted Revenues $ 3,146 $ 3,146 Cost of sales 1,220 (20 ) — (8 ) (59 ) (2 ) 1,131 Gross profit 1,926 2,015 Gross margin 61.2 % 64.0 % Selling, general and administrative 886 (90 ) — (32 ) — (1 ) 763 Research and development 257 (6 ) — (7 ) — — 244 Acquired in-process research and development and milestones 8 — — — — — 8 Restructuring costs 4 — (4 ) — — — — Interest expense 264 — — — — — 264 Exchange losses 11 — — — — — 11 Other expense (income), net 7 (10 ) — — — — (3 ) 2,657 2,418 Income before income taxes 489 728 Taxes on income 70 26 1 8 11 — 116 Net income $ 419 $ 612 Earnings per share - Diluted $ 1.64 $ 2.39 (1) Represents one-time costs. Spin-related includes costs from the separation of Merck & Co., Inc., Rahway, NJ, US and Other primarily includes inventory step-up amortization and legal reserves. Six Months Ended June 30, 2022 GAAP Spin related Costs(1) Restructuring Stock-based Compensation Amortization Other(1) Non-GAAP Adjusted Revenues $ 3,152 $ 3,152 Cost of sales 1,149 (10 ) — (6 ) (56 ) (14 ) 1,063 Gross profit 2,003 2,089 Gross margin 63.5 % 66.3 % Selling, general and administrative 794 (53 ) — (23 ) — — 718 Research and development 202 (6 ) — (5 ) — (1 ) 190 Acquired in-process research and development and 97 — — — — — 97 Restructuring costs — — — — — — — Interest expense 195 — — — — — 195 Exchange gains (25 ) — — — — — (25 ) Other expense (income), net 11 (14 ) — — — — (3 ) 2,423 2,235 Income before income taxes 729 917 Taxes on income 147 14 — 5 9 3 178 Net income $ 582 $ 739 Earnings per share - Diluted $ 2.28 $ 2.90 (1) Represents one-time costs. Spin-related includes costs from the separation of Merck & Co., Inc., Rahway, NJ, US and Other primarily includes inventory step-up amortization and legal reserves. TABLE 5 Organon & Co. Reconciliation of GAAP Income Before Income Taxes to Adjusted EBITDA (Unaudited, $ in millions) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Income before income taxes $ 254 $ 287 $ 489 $ 729 Depreciation 28 22 56 47 Amortization 30 28 59 56 Interest expense 132 98 264 195 EBITDA $ 444 $ 435 $ 868 $ 1,027 Restructuring costs — — 4 — One-time costs (1) 61 58 129 98 Stock-based compensation 25 19 47 34 Adjusted EBITDA $ 530 $ 512 $ 1,048 $ 1,159 Adjusted EBITDA margin 33.0 % 32.3 % 33.3 % 36.8 % (1) One-time costs primarily include costs incurred in connection with the spin-off of Organon, inventory step up adjustments and legal reserves.

SAB Strengthens GL CHEMTEC’s Mission of Being the Trusted North American CDMO for Small Molecule R&D, Scale-Up and Integrated Drug Delivery Solutions OAKVILLE, Ontario--(BUSINESS WIRE)-- GL CHEMTEC (“GLC”), a specialist in advanced chemistry R&D and scale-up services to support Active Pharmaceutical Ingredient (“API”) development, and the development of advanced materials for drug delivery, medical devices, and other life science applications, today announced the formation of its Scientific Advisory Board comprised of distinguished leaders in Small Molecule R&D (Chemistry/Biology), Process Development & Scale-Up, Green Chemistry, Medical Devices and Drug Delivery. Lisa Studnicki Hunt, Ph.D., COO and Co-Founder of GLC commented, “We are proud and honoured to introduce GL CHEMTEC’s inaugural SAB. This is a team of world leaders in their respective fields who bring a wealth of experience to our company during our next phase of growth. We can’t thank these outstanding individuals enough for committing their time and expertise to GL CHEMTEC’s success.” Gamil Alhakimi, Ph.D., MBA, CEO and Co-Founder of GLC commented, “It is a great privilege to welcome our distinguished Scientific Advisory Board members to the GL CHEMTEC family. Their vast experience and accomplishments in various scientific disciplines will be invaluable in supporting our dedication to innovation and growth within Small Molecule R&D, Scale-Up, and Integrated Drug Delivery Solutions. Their collaboration with our team will ensure we remain at the forefront of the industry, providing our clients with unparalleled expertise and cutting-edge solutions for years to come.” The founding members of the GL CHEMTEC Scientific Advisory Board are: Dr. John Warner is one of the cofounders of the field of green chemistry, coauthoring the defining text “Green Chemistry: Theory and Practice” and articulating the 12 principles of green chemistry with Paul Anastas. John has over 100 publications providing foundational work in the fields of noncovalent derivatization, polymer photochemistry, metal oxide semiconductors and synthetic organic chemistry. John received his BS in Chemistry from UMASS Boston, and his PhD in Chemistry from Princeton University. After working at the Polaroid Corporation for nearly a decade, he then served as tenured full professor at UMASS Boston and Lowell (Chemistry and Plastics Engineering). Dr. Mark Hellberg retired from Novartis where he built a Chemical Technologies group that developed an integrated model of chemical innovation as a key component of the discovery process spanning hit expansion through candidate advancement. Prior to joining Novartis, Mark was the Head of Research Chemistry at Alcon where he was responsible for medicinal chemistry, research, analytical and scale-up teams (initial synthesis through Phase 1 GMP material). He spent over 20 years at Alcon initially leading internal medicinal chemistry teams and ultimately serving as a member of both research and development governance boards representing all aspects of research chemistry. At Alcon he gained board experience in all aspects of ophthalmic drug discovery. Dr. Wolf-Ulrich Nickel has a PhD. In Organic Chemistry, which he earned at the University of Hamburg/Germany. After a Postdoc at ETH in Zürich/CH he entered the pharmaceutical industry in R&D area as his professional calling. From lab director in medicinal chemistry to research team leader, then project manager and later global program director, he contributed and was responsible for more than 40 drug development programs in ten therapeutic areas. He worked with increasing responsibilities and extended geographic foot print at companies Hoechst AG, HMR, Aventis, Kyowa-Kirin, Celgene and lately at Alcon and Novartis. Key areas were Ophthalmology/Otolaringology, Cardio-Metabolic-Renal, Neuroscience and Inflammatory diseases. Dr. Nickel contributed to more than forty patent applications and authored several academic and industrial publications with focus on chemistry and presented case studies at several project management and clinical association conferences. He retired recently from Novartis Pharmaceutical Corporation in US and continued to serve as consultant for program strategy reviews and scientific advisory boards. Dr. Rob Larsen is an organic chemist having received his BS degree in Chemistry from the University of Michigan-Dearborn and his PhD in Organic Chemistry with Professor Joseph P. Marino at the University of Michigan in Ann Arbor in 1982. He worked in the pharmaceutical industry for over 39 years in the area of Process Research & Development at Merck, Amgen, Alcon and Novartis having retired from Novartis in 2021. He rose through the ranks of Process R&D achieving the position of Executive Director. Over his career he was on the development teams that lead to the commercialization of rizatriptan, losartan, montelukast, etoricoxib, aprepitant, and finafloxacin. He is a co-author on 95 papers, 11 review articles and was the Book Editor for Topics in Organometallic Chemistry, Organometallics in Process Chemistry, Volume 6. His interests over his career covered heterocyclic chemistry, organometallics, in particular the application of palladium in processes, and biocatalysis. Dr. Kasey Minick has forty-one years of hands-on experience with Pharmaceutical (NDA & ANDA), OTC (Dry Eye, Ophthalmic Tears, Allergy, Vitamins, Oral liquids) and Medical Device (Contact Lenses and Contact Lens Care) Formulation Research and Development, Formulation Process Development and Engineering, Technical Transfer (R&D to Manufacturing), Product Registration and Project Management of full-scale Pharmaceutical and/or Medical Device projects from NCE/pre-clinical research to POC (proof of concept) through clinical studies to commercial transfer and commercial registration and product launch. Dr. Minick is a Pharm.D. and has worked for Alcon, CIBA Vision, Cardinal Health and Novartis. Dr. David Mangelsdorf is Professor and Chair of the Department of Pharmacology at UT Southwestern Medical Center and Investigator of the Howard Hughes Medical Institute. He holds the Alfred G. Gilman Distinguished Chair in Pharmacology and Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology. He is also an elected member of the U.S. National Academy of Sciences. Dr. Mangelsdorf is a molecular biologist and world leader in nuclear receptor and endocrine FGF signaling. Together with his scientific partner Steven Kliewer, he has discovered several of the orphan nuclear receptors, identified their hormonal ligands, and demonstrated their importance as therapeutic targets. About GL CHEMTEC: For almost 20 years, GL CHEMTEC (“GLC”) has been a leading chemistry-based CRO supporting the pharmaceutical industry and broader Life Sciences sector. GLC specializes in advanced multi-step organic synthesis, process R&D, and scale-up services to support API development, as well as advanced materials for medical devices, drug delivery, and other Life Science applications. GLC has a particular focus on the development of new bio-based materials inspired by the 12 Principles of Green Chemistry. Operating from two modern, North American-based facilities, GLC has the experience and capabilities to deliver materials ranging from milligrams to hundreds of kilos. GLC is the partner of choice from small emerging Biotechs to Big Pharma and other Life Science organizations, and is recognized for its speed and client-centric business model. Visit us at .